Evaluation of the mutagenicity of 1-hydrazino-4-(3,5-dimethyl-1-pyrazolyl) pyridazino[4,5-b]indole

Arzneimittelforschung. 1994 Mar;44(3):310-2.

Abstract

The mutagenic potential of 1-hydrazino-4-(3,5-dimethyl-1-pyrazolyl) pyridazino [4,5-b]indole(A80a, CAS 135561-93-2), a new antihypertensive agent, was investigated in 3 test systems, according to the current EC Guidelines: Ames test with strains TA1535, TA1537, TA98 and TA100, SCE (sister chromatid exchange) test in V79 cells and micronucleus test in Swiss mice. No indications for a mutagenic potential were detected in bacteria and mice; positive results were obtained in eukaryotic cells. The potential for inducing chromosome aberrations in eukaryotic cells will be studied.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / toxicity*
  • Cell Line
  • In Vitro Techniques
  • Indoles / toxicity*
  • Male
  • Mice
  • Micronucleus Tests
  • Mutagenicity Tests
  • Mutagens / toxicity*
  • Pyridazines / toxicity*
  • Rats
  • Rats, Wistar
  • Salmonella typhimurium / drug effects
  • Salmonella typhimurium / genetics
  • Sister Chromatid Exchange / drug effects

Substances

  • Antihypertensive Agents
  • Indoles
  • Mutagens
  • Pyridazines
  • 1-hydrazino-4-(3,5-dimethyl)-1-pyrazolyl-5H-pyridazino(4,5-b)indole